Methotrexate for refractory adult atopic dermatitis leads to alterations in cutaneous IL-31 and IL-31RA expression.

ABSTRACT:

Background

Methotrexate (MTX) is an alternative treatment for patients with moderate/severe atopic dermatitis (AD).

Objective

The authors evaluated the effect of MTX on the cutaneous expression of cytokines and chemokines that are involved in the inflammatory response in adult AD patients who received treatment with methotrexate for 24 weeks.

Methods

The authors conducted a prospective single-institution cohort study with 12 adults with moderate/severe AD who received oral MTX (15 mg/wk for 24 wks) and 10 non-atopic matched controls. The comparison was made of skin biopsies of lesional and non-lesional skin, pre- and post MTX treatment. The authors analyzed mean epidermal thickness and expression of IL-31, IL-31RA, OSMR, TSLP, Ki67, IL-4 mRNA, IL-6, IL-10, TNF-α, IFN-

SUBMITTER: Samorano LP 

PROVIDER: S-EPMC10964359 | biostudies-literature | 2024 Jan-Feb

REPOSITORIES: biostudies-literature